Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA A Cancer J Clinicians. 2023;73:17–48.

Google Scholar 

Herzog TJ, Armstrong DK. First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer. In: Post TW (ed). UpToDate. UpToDate: Waltham, MA, 2023.

SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute. 2023. https://seer.cancer.gov/statistics-network/explorer/ (accessed 25 Jul2023).

Oza AM, Castonguay V, Tsoref D, Diaz-Padilla I, Karakasis K, Mackay H, et al. Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol. 2011;18:S20–27.

PubMed  PubMed Central  Google Scholar 

Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107:588–91.

CAS  PubMed  PubMed Central  Google Scholar 

Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. J Exp Pharm. 2021;13:303–28.

Google Scholar 

Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD, et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2012;125:677–82.

CAS  PubMed  Google Scholar 

Du P, Wang Y, Chen L, Gan Y, Wu Q. High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer. Oncol Lett. 2016;12:857–62.

CAS  PubMed  PubMed Central  Google Scholar 

Stefanou DT, Souliotis VL, Zakopoulou R, Liontos M, Bamias A. DNA damage repair: predictor of platinum efficacy in ovarian cancer? Biomedicines. 2021;10:82.

PubMed  PubMed Central  Google Scholar 

Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, et al. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021;40:6395–6405.

CAS  PubMed  PubMed Central  Google Scholar 

Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.

PubMed  Google Scholar 

Barnes BM, Nelson L, Tighe A, Burghel GJ, Lin I-H, Desai S, et al. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med. 2021;13:140.

CAS  PubMed  PubMed Central  Google Scholar 

Hu Z, Cunnea P, Zhong Z, Lu H, Osagie OI, Campo L, et al. The Oxford classic links epithelial-to-mesenchymal transition to immunosuppression in poor prognosis ovarian cancers. Clin Cancer Res. 2021;27:1570–79.

CAS  PubMed  Google Scholar 

Lang JD, Selleck W, Striker S, Hipschman NA, Kofman R, Karnezis AN, et al. Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide. 2023. https://doi.org/10.1101/2023.09.08.556863.

Steele CD, Abbasi A, Islam SMA, Bowes AL, Khandekar A, Haase K, et al. Signatures of copy number alterations in human cancer. Nature. 2022;606:984–91.

CAS  PubMed  PubMed Central  Google Scholar 

Bergstrom EN, Huang MN, Mahto U, Barnes M, Stratton MR, Rozen SG, et al. SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events. BMC Genomics. 2019;20:685.

PubMed  PubMed Central  Google Scholar 

Díaz-Gay M, Vangara R, Barnes M, Wang X, Islam SMA, Vermes I, et al. Assigning mutational signatures to individual samples and individual somatic mutations with SigProfilerAssignment. Bioinformatics. 2023;39:btad756.

PubMed  PubMed Central  Google Scholar 

Yamamoto H, Hirasawa A. Homologous recombination deficiencies and hereditary tumors. Int J Mol Sci. 2021;23:348.

PubMed  PubMed Central  Google Scholar 

Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F, et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018;4:16.

PubMed  PubMed Central  Google Scholar 

Warren A, Chen Y, Jones A, Shibue T, Hahn WC, Boehm JS, et al. Global computational alignment of tumor and cell line transcriptional profiles. Nat Commun. 2021;12:22.

CAS  PubMed  PubMed Central  Google Scholar 

Blayney JK, Davison T, McCabe N, Walker S, Keating K, Delaney T, et al. Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line. Nucleic Acids Res. 2016;44:e137.

PubMed  PubMed Central  Google Scholar 

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS One. 2013;8:e72162.

CAS  PubMed  PubMed Central  Google Scholar 

Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, et al. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun. 2016;7:12645.

CAS  PubMed  PubMed Central  Google Scholar 

Meeson KE, Schwartz J-M. Constraint-based modelling predicts metabolic signatures of low and high-grade serous ovarian cancer. npj Syst Biol Appl. 2024;10:96.

PubMed  PubMed Central  Google Scholar 

Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569:503–08.

CAS  PubMed  PubMed Central  Google Scholar 

Provencher DM, Lounis H, Champoux L, Tétrault M, Manderson EN, Wang JC, et al. Characterization of four novel epithelial ovarian cancer cell lines. Vitr Cell Dev Biol Anim. 2000;36:357–61.

CAS  Google Scholar 

Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, et al. Clinical pharmacokinetics of carboplatin. J Clin Pharm. 1988;28:208–15.

CAS  Google Scholar 

Gaver RC, Colombo N, Green MD, George AM, Deeb G, Morris AD, et al. The disposition of carboplatin in ovarian cancer patients. Cancer Chemother Pharm. 1988;22:263–70.

CAS  Google Scholar 

Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res. 2007;13:6410–18.

CAS  PubMed  Google Scholar 

Nagai N, Ogata H, Wada Y, Tsujino D, Someya K, Ohno T, et al. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharm. 1998;38:1025–34.

CAS  Google Scholar 

Ikeda K, Terashima M, Kawamura H, Takiyama I, Koeda K, Takagane A, et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol. 1998;28:168–75.

CAS  PubMed  Google Scholar 

Bonetti A, Franceschi T, Apostoli P, Cetto GL, Recaldin E, Molino A, et al. Cisplatin pharmacokinetics in elderly patients. Ther Drug Monit. 1994;16:477–82.

CAS  PubMed  Google Scholar 

Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 1988;48:6166–72.

CAS  PubMed  Google Scholar 

Cooke SL, Ng CKY, Melnyk N, Garcia MJ, Hardcastle T, Temple J, et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene. 2010;29:4905–13.

CAS  PubMed  PubMed Central  Google Scholar 

Beaufort CM, Helmijr JCA, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One. 2014;9:e103988.

PubMed  PubMed Central  Google Scholar 

Witkowski L, Goudie C, Ramos P, Boshari T, Brunet J-S, Karnezis AN, et al. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecol Oncol. 2016;141:454–60.

PubMed  PubMed Central  Google Scholar 

McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, et al. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol. 2014;4:40.

PubMed  PubMed Central  Google Scholar 

Zhang L-M, Li M, Tian C-C, Wang T-T, Mi S-F. CCAAT enhancer binding protein α suppresses proliferation, metastasis, and epithelial-mesenchymal transition of ovarian cancer cells via suppressing the Wnt/β-catenin signaling. Neoplasma. 2021;68:602–12.

CAS  PubMed  Google Scholar 

Li L, Yang W-T, Zheng P-S, Liu X-F. SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/β-catenin signaling pathway via trans-suppressing β-catenin in cervical cancer. Cell Death Dis. 2018;9:741.

CAS